Skip to main content

Closed

ABCL: AbCellera Biologics Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth-24.2% / yr

Operating margin-267.6%

ROIC-13.8%

Financially safe

Stretched

Debt / equity0.15×

Interest coverage0.0×

Current ratio14.05×

AbCellera Biologics Inc.

ABCLNASDAQ Global Select·USD·Closed

AbCellera Biologics Inc.

ABCLNASDAQ·USD·Closed

$5.71

+0.35%

$5.71

+$0.02 (0.35%)

52W Range

52thpctl

Volume

0.65×avg

Mkt Cap

1.74BUSD

P/E

-11.9TTM

Div Yield

–ann

52W Range

52thpctl

Volume

0.65×avg

Market Cap

1.74BUSD

P/E Ratio

-11.9TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings